Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESTIMABL2: Radioiodine Ablation in Low Risk Thyroid Cancer
NCT01837745Phase 3Active, not recruiting
- Sponsor
- Gustave Roussy
- Start
- May 2013
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of iodine-131 in differentiated thyroid cancer (DTC), sponsored by Gustave Roussy. Started May 2013; status: active, not recruiting.
02
Drugs
iodine-131
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT01837745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01837745.